Anti-inflammatory effects of AT1 receptor blockade provide end-organ protection in stroke-prone rats independently from blood pressure fall

Journal of Pharmacology and Experimental Therapeutics

Volumn 311, Issue 3, 2004, Pages 989-995

  Sironi, Luigi ^a   Gelosa, Paolo ^a   Guerrini, Uliano ^a   Banfi, Cristina ^a   Crippa, Veronica ^a   Brioschi, Maura ^a,c   Gianazza, Elisabetta ^a   Nobili, Elena ^a   Gianella, Anita ^a   De Gasparo, Marc ^b   Tremoli, Elena ^a,c  

^a UNIVERSITY OF MILAN   (Italy)

^b MG Consulting Co   (Switzerland)

^c CENTRO CARDIOLOGICO MONZINO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; VALSARTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD PRESSURE REGULATION; BRAIN INJURY; CELL INFILTRATION; CONTROLLED STUDY; DRUG EFFECT; HYPERTENSION; INFLAMMATION; KIDNEY DISEASE; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; RECEPTOR BLOCKING; SPONTANEOUSLY HYPERTENSIVE RAT; STROKE; URINARY EXCRETION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ANTI-INFLAMMATORY AGENTS; BLOOD PRESSURE; BODY WEIGHT; BRAIN; CEREBROVASCULAR ACCIDENT; CHEMOKINE CCL2; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-1; KIDNEY; MAGNETIC RESONANCE IMAGING; MALE; PROTEINURIA; RATS; RATS, INBRED SHR; RNA, MESSENGER; SURVIVAL ANALYSIS; TETRAZOLES; TRANSFORMING GROWTH FACTOR BETA; VALINE;

EID: 10044279181     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.104.072066     Document Type: Article

References (36)

1. Abrahamsen CT, Barone FC, Campbell WCJ, Nelson AH, Contino LC, Pullen MA, Grygielko ET, Edwards RM, Laping NJ, and Brooks DP (2002) The angiotensin type 1 receptor antagonist, eprosartan, attenuates the progression of renal disease in spontaneously hypertensive stroke-prone rats with accelerated hypertension. J Pharmacol Exp Ther 301:21-28.
2. Balduini W, Mazzoni E, Carloni S, De Simoni MG, Perego C, Sironi L, and Cimino M (2003) Prophylactic but not delayed administration of simvastatin protects against long-lasting cognitive and morphological consequences of neonatal hypoxic-ischemic brain injury, reduces interleukin-1beta and tumor necrosis factor-alpha mRNA induction and does not affect endothelial nitric oxide synthase expression. Stroke 34:2007-2012.
3. Barone FC, Nelson AH, Ohlstein EH, Willette RN, Sealey JE, Laragh JH, Campbell WCJ, and Feuerstein GZ (1996) Chronic carvedilol reduces mortality and renal damage in hypertensive stroke-prone rats. J Pharmacol Exp Ther 279:948-955.
4. Bergstrom J, Lindholm B, Lacson E Jr, Owen W Jr, Lowrie EG, Glassock RJ, Ikizler TA, Wessels FJ, Moldawer LL, Wanner C, and Zimmermann J (2000) What are the causes and consequences of the chronic inflammatory state in chronic dialysis patients? Semin Dial 13:163-175.
5. Blezer EL, Nicolay K, Goldschmeding R, Jansen GH, Koomans HA, Rabelink TJ, and Joles JA (1999) Early-onset but not late-onset endothelin-A-receptor blockade can modulate hypertension, cerebral edema and proteinuria in stroke-prone hypertensive rats. Hypertension 33:137-144.
6. Blezer EL, Schurink M, Nicolay K, Bar PR, Jansen GH, Koomans HA, and Joles JA (1998) Proteinuria precedes cerebral edema in stroke-prone rats: a magnetic resonance imaging study. Stroke 29:167-174.
7. Brasier AR, Recinos A 3rd, and Eledrisi MS (2002) Vascular inflammation and renin-angiotensin system. Arterioscler Thromb Vasc Biol 22:1257-1266.
8. Candido R, Allen TJ, Lassila M, Cao Z, Thallas V, Cooper ME, and Jandeleit-Dahm KA (2004) Irbesartan but not amlodipine suppresses diabetes-associated atherosclerosis. Circulation 109:1536-1542.
9. Dandona P, Kumar V, Aljada A, Ghanim H, Syed T, Hofmayer D, Mohanty P, Tripathy D, and Garg R (2003) Angiotensin II receptor blocker valsartan suppresses reactive oxygen species generation in leukocytes, nuclear factor-kappa B, in mononuclear cells of normal subjects: evidence of an anti-inflammatory action. J Clin Endocrinol Metab 88:4496-4501.
10. de Maat MP, Kluft C, Gram J, and Jespersen J (2003) Angiotensin- converting enzyme inhibitor trandolapril does not affect C-reactive protein levels in myocardial-infarction patients. Circulation 108:e113.
11. Dinarello CA (1996) Biologic basis for interleukin-1 in disease. Blood 87:2095-2147.
12. Dzau VJ (2001) Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension 37:1047-1052.
13. Egido J (1996) Vasoactive hormones and renal sclerosis (Nephrology Forum). Kidney Int 49:478-597.
14. Gahnem F, von Lutterotti N, Camargo MJ, Laragh JH, and Sealey JE (1994) Angiotensinogen dependency of blood pressure in two high-renin hypertensive rat models. Am J Hypertens 10:899-904.
15. Glurich I, Grossi S, Albini B, Ho A, Shah R, Zeid M, Baumann H, Genco RJ, and De Nardin E (2002) Systemic inflammation in cardiovascular and periodontal disease: comparative study. Clin Diagn Lab Immunol 9:425-432.
16. Guerrini U, Sironi L, Tremoli E, Cimino M, Pollo B, Calvio AM, Paoletti R, and Asdente M (2002) New insights into brain damage in stroke-prone rats: a nuclear magnetic imaging study. Stroke 33:825-830.
17. Hilgers KF, Hartner A, Porst M, Veelken R, and Mann JFE (2001) Angiotensin II type 1 receptor blockade prevents lethal malignant hypertension. Relation to kidney inflammation. Circulation 104:1436-1440.
18. Klingbeil AU, John S, Schneider MP, Jacobi J, Weidinger G, and Schmieder RE (2002) AT1-receptor blockade improves augmentation index: a double-blind, randomized, controlled study. J Hypertens 20:2423-2428.
19. Lewis EJ (2002) The role of angiotensin II receptor blockers in preventing the progression of renal disease in patients with type 2 diabetes. Am J Hypertens 10:123S-128S.
20. Luft FC (2002) Proinflammatory effects of angiotensin II and endothelin: targets for progression of cardiovascular and renal diseases. Curr Opin Nephrol Hypertens 11:59-66.
21. Marks L, Carswell HV, Peters EE, Graham DI, Patterson J, Dominiczak AF, and Macrae IM (2001) Characterization of the microglial response to cerebral ischemia in the stroke-prone spontaneously hypertensive rat. Hypertension 38:116-122.
22. Muller DN, Dechend R, Mervaala EM, Park JK, Schmidt F, Fiebeler A, Theuer J, Breu V, Ganten D, Haller H, and Luft FC (2000) NF-kappaB inhibition ameliorates angiotensin II-induced inflammatory damage in rats. Hypertension 35:193-201.
23. Nataraj C, Oliverio MI, Mannon RB, Mannon PJ, Audoly LP, Amuchastegui CS, Ruiz P, Smithies O, and Coffman TM (1999) Angiotensin II regulates cellular immune responses through a calcineurin-dependent pathway. J Clin Investig 104:1693-1701.
24. Pepys MB and Hirschfield GM (2003) C-reactive protein: a critical update. J Clin Investig 111:1805-1812.
25. Rocha R, Chander PN, Zuckerman A, and Stier CT Jr (1999) Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. Hypertension 33:232-237.
26. Ruiz-Ortega M, Bustos C, Hernandez-Presa MA, Lorenzo O, Plaza JJ, and Egido J (1998) Angiotensin II participates in mononuclear cell recruitment in experimental immune complex nephritis through nuclear factor-kappa B activation and monocyte chemoattractant protein-1 synthesis. J Immunol 161:430-439.
27. Ruiz-Ortega M, Lorenzo O, Suzuki Y, Ruperez M, and Egido J (2001) Proinflammatory actions of angiotensins. Curr Opin Nephrol Hypertens 10:321-329.
28. Ruiz-Ortega M, Ruperez M, Larenzo O, Esteban V, Blanco J, Mezzano S, and Egido J (2002) Angiotensin II regulates the synthesis of proinflammatory cytokines and chemokines in the kidney. Kidney Int Suppl 82:12-22.
29. Sadoshima J (2000) Cytokine actions of angiotensin II. Circ Res 86:1187-1199.
30. Sharma K, Jin Y, Guo J, and Ziyadeh FN (1996) Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes 45:522-530.
31. Sironi L, Calvio AM, Bellosta S, Lodetti B, Guerrini U, Monetti M, Tremoli E, and Mussoni L (2003) Endogenous proteolytic activity in a rat model of spontaneous cerebral stroke. Brain Res 974:184-192.
32. Sironi L, Tremoli E, Miller I, Guerrini U, Calvio AM, Eberini I, Gemeiner M, Asdente M, Paoletti R, and Gianazza E (2001) Acute-phase proteins before cerebral ischemia in stroke-prone rats: identification by proteomics. Stroke 32:753-760.
33. Stuveling EM, Hillege HL, Bakker SJ, Gans RO, De Jong PE, and De Zeeuw D (2003) C-reactive protein is associated with renal function abnormalities in a non-diabetic population. Kidney Int 63:654-661.
34. Tummala PE, Chen XL, Sundell CL, Laursen JB, Hammes CP, Alexander RW, Harrison DG, and Medford RM (1999) Angiotensin II induces vascular cell adhesion molecule-1 expression in rat vasculature: A potential link between the reninangiotensin system and atherosclerosis. Circulation 100:1223-1229.
35. Viberti G, Wheeldon NM, and MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators (2002) Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 106:672-678.
36. Yu XQ, Fan JM, Nikolic-Paterson DJ, Yang N, Mu W, Pichler R, Johnson RJ, Atkins RC, and Lan HY (1999) IL-1 up-regulates osteopontin expression in experimental crescentic glomerulonephritis in the rat. Am J Pathol 154:833-841.